Other Events ·
Sanofi announced three key developments in June 2026
SNYSanofi
Sanofi announced three key developments in June 2026. The company launched its 2026 global employee stock purchase plan on June 4. On June 8, the EU approved Sarclisa subcutaneous as the first anticancer treatment administered via an on-body injector. On June 10, the company provided an update on the MOBILIZE phase 3 study of riliprubart for chronic inflammatory demyelinating polyneuropathy. Sanofi is a pharmaceutical company that develops and manufactures vaccines, specialty care, and general medicines.